Home・Akcijų sąrašas・Moderna Inc

Moderna Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

56.94 3.32

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

55.11

Max

58.19

Pagrindiniai rodikliai
By Trading Economics
Pajamos	561M -782M
Pardavimai	-244M 145M
Pelnas, tenkantis vienai akcijai	-1.97
Pelno marža	-539.31
Darbuotojai	4,700
EBITDA	554M -704M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-11.28% downside

Dividendai
By Acuity
Kitas uždarbis	2026-11-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-194M 22B
Ankstesnė atidarymo kaina	53.62
Ankstesnė uždarymo kaina	56.94

Naujienos nuotaikos

By Acuity

29%

71%

110 / 340 reitingas Healthcare

Moderna Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-04 20:07; UTC

Social Media

News

Moderna initiates Phase 1 trial for mRNA-1469 vaccine, backed by CEPI's $50 million funding. Shares are higher despite earlier session pullback.

2026-08-03 20:03; UTC

News

Moderna Inc. shares are advancing as Citigroup raises its price target to $60 amid broader market strength and gains in major tech stocks.

2026-07-31 23:26; UTC

Moderna Inc. shares are lower in after-hours trading, continuing a decline from Friday's close without any specific news to explain the movement.

2026-07-30 23:51; UTC

Moderna Inc shares are higher in after-market trading, driven by a significant advance in the overall market, despite earlier fluctuations during the session.

2026-07-29 23:51; UTC

Moderna Inc is rising in after-market trading, aligning with broader market gains. The stock showed volatility earlier in the session without specific news driving the move.

2026-07-28 18:36; UTC

Moderna Inc shares are lower today, continuing a decline from Monday's close amid risk-off sentiment following significant declines in Asian markets.

2026-07-27 19:07; UTC

Social Media

Moderna Inc. is advancing as it initiates a Phase 1 trial for its mRNA-4200 cancer vaccine, with the first U.S. participant dosed on July 16, 2026.

2026-07-24 19:03; UTC

Social Media

News

Moderna Inc shares are lower today amid mixed options sentiment and increased demand for downside protection ahead of its upcoming earnings report.

2026-07-23 19:56; UTC

Social Media

News

Moderna Inc shares are lower, trading around $57.25, as options activity remains light. An mRNA vaccine is set for a Phase 1 trial in August.

2026-07-21 20:07; UTC

News

Social Media

Goldman Sachs raised Moderna's price target to $49.00 while maintaining a Neutral rating, reflecting a more favorable outlook on the company's valuation. Shares are higher today.

2026-07-20 23:46; UTC

Moderna Inc shares are lower in after-market hours amid rising Treasury yields and broader market trends, with no specific company news identified.

Akcijų palyginimas

Kainos pokytis

Moderna Inc Prognozė

Kainos tikslas

By TipRanks

-11.28% į apačią

12 mėnesių prognozė

Vidutinis 48.92 USD -11.28%

Aukščiausias 77 USD

Žemiausias 39 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Moderna Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

15 ratings

Pirkti

Laikyti

Parduoti

Remiantis 15 analitikų, pateikusių Moderna Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

110 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Moderna Inc

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.